[Therapy of gout in 2024]

Area of Science:

• Rheumatology
• Pharmacology

Background:

• Gout treatment requires both anti-inflammatory therapy for acute flares and long-term uric acid reduction.
• Intra-articular steroids are optimal for acute gouty arthritis; systemic steroids, NSAIDs, and colchicine are alternatives.
• Long-term prophylaxis involves colchicine, NSAIDs, or low-dose steroids.

Purpose of the Study:

• To outline the pharmacological strategies for managing gout, focusing on uric acid reduction.
• To emphasize the importance of the "treat to target" approach for serum uric acid levels.
• To detail the recommended titration strategies for xanthine oxidase inhibitors.

Main Methods:

• Discussion of pharmacological agents including xanthine oxidase inhibitors (allopurinol, febuxostat).
• Explanation of the "start low, go slow" titration strategy for medication dosing.
• Highlighting the significance of patient adherence and management of comorbidities.

Main Results:

• Xanthine oxidase inhibitors, allopurinol and febuxostat, are primary agents for long-term uric acid lowering.
• The "start low, go slow" method minimizes relapse risk and hypersensitivity syndrome with allopurinol.
• Serum uric acid below 360 µmol/l is the therapeutic target.
• Medication non-adherence is a common reason for inadequate uric acid reduction.

Conclusions:

• Pharmacological uric acid reduction is the cornerstone of gout therapy.
• Careful dose titration of allopurinol and febuxostat is essential for efficacy and safety.
• Addressing comorbidities and ensuring medication adherence are critical for successful gout management.